HYPR — Hyperfine, Inc.

Summary of HYPR Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $5.3 million, up 128% year-over-year from $2.3 million in Q4 2024.
• Full Year Revenue: $13.6 million, a 5% increase from $12.9 million in 2024.
• Gross Profit (Q4): $2.7 million, up 226% year-over-year, with a gross margin of 50.9%.
• Full Year Gross Profit: $6.8 million, a 15% increase, with a gross margin of 49.8%.
• Net Loss (Q4): $5.9 million ($0.06 per share), improved from a loss of $10.4 million ($0.14 per share) in Q4 2024.
• Full Year Net Loss: $35.6 million ($0.43 per share), down from a loss of $40.7 million ($0.56 per share) in 2024.
• Cash Position: $35.1 million in cash and equivalents as of December 31, 2025.

2. Strategic Updates and Business Highlights

• Product Launches: Successful introduction of the next-generation Swoop system and Optive AI software, enhancing diagnostic capabilities.
• Market Expansion: FDA clearance for the Swoop system in India and ongoing international market penetration with software available in 10 European languages.
• Clinical Validation: Positive feedback from the medical community on image quality and economic value, leading to increased interest and deal activations.
• Operational Efficiency: Reduced cash burn by 30% in Q4 2025 compared to Q4 2024, reflecting improved operational efficiency.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $20 million to $22 million, representing a year-over-year growth of approximately 55%.
• Gross Margin Outlook: Anticipated to remain between 50% to 55% for 2026, with expectations for higher margins in the second half of the year.
• Cash Burn Expectations: Projected to be between $26 million to $28 million for 2026, indicating a 10% year-over-year decline.

4. Bad News, Challenges, or Points of Concern

• Sales Variability: Larger deals are subject to budget cycles, potentially leading to variability in quarterly revenue.
• Service Revenue Decline: Lower service revenue in Q4 due to accounting adjustments related to technology upgrades, which may affect future service revenue growth.
• Market Competition: While the Swoop system shows strong clinical value, competition in the medical imaging market remains a concern.

5. Notable Q&A Insights

• Pipeline Strength: The pipeline is described as the strongest ever, with multiple IDN deals in progress, though these may take time to materialize due to procurement processes.
• Pricing Strategy: The MSRP for the next-generation Swoop system increased to $590,000, which is expected to enhance ROI for hospitals and drive sales.
• Service Revenue Trajectory: Future service revenue is expected to grow as more devices are deployed, despite a temporary decline in Q4 due to accounting adjustments.

Overall, Hyperfine demonstrated strong growth in Q4 2025, driven by product innovations and market expansion, while also addressing challenges related to sales variability and service revenue. The company is optimistic about its future growth trajectory, supported by a solid financial position and operational efficiencies.